KA2507   Click here for help

GtoPdb Ligand ID: 12269

Compound class: Synthetic organic
Comment: KA2507 ia a clinical stage, selective and orally bioavailable HDAC6 inhibitor, that was designed for potential to treat advanced solid malignancies [1]. This compound produces a direct antitumour effect, and it promotes an antitumour immune response.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 104.13
Molecular weight 322.12
XLogP 0.92
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES ONC(=O)c1ccc(cc1)CN(c1cnccn1)c1cnccn1
Isomeric SMILES c1cc(ccc1CN(c1nccnc1)c1nccnc1)C(=O)NO
InChI InChI=1S/C16H14N6O2/c23-16(21-24)13-3-1-12(2-4-13)11-22(14-9-17-5-7-19-14)15-10-18-6-8-20-15/h1-10,24H,11H2,(H,21,23)
InChI Key LXHMTDHBMRZSHJ-UHFFFAOYSA-N
Classification Click here for help
Compound class Synthetic organic
IUPAC Name Click here for help
4-[[di(pyrazin-2-yl)amino]methyl]-N-hydroxybenzamide
Database Links Click here for help
GtoPdb PubChem SID 473153857
PubChem CID 117703516
Search Google for chemical match using the InChIKey LXHMTDHBMRZSHJ-UHFFFAOYSA-N
Search Google for chemicals with the same backbone LXHMTDHBMRZSHJ
UniChem Compound Search for chemical match using the InChIKey LXHMTDHBMRZSHJ-UHFFFAOYSA-N
UniChem Connectivity Search for chemical match using the InChIKey LXHMTDHBMRZSHJ-UHFFFAOYSA-N